Trial Profile
A Randomised, Placebo-controlled, Parallel Group Single Dose Study of GW856553 in Patients With Active RA to Investigate the C-Reactive Protein (CRP) Dose Response Relationship.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Losmapimod (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors GSK
- 13 Jan 2012 Actual patient number changed from 48 to 51 according to ClinicalTrials.gov.
- 13 Jan 2012 Actual end date ( Nov 2006) added as reported by ClinicalTrials.gov.
- 21 Jun 2007 Status changed from recruitng to completed.